Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing

Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing

Background Autologous CD19 chimeric antigen receptor (CAR) T-cell therapy leads to durable responses and improved survival in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Among approved CAR T-cell products, axicabtagene ciloleucel (axi-cel; CD19/CD28) has greater real-world...

Full description

Saved in:
Bibliographic Details
Main Authors: Xuefeng Wang, Paulo C Rodriguez, Frederick L Locke, Xiaoqing Yu, Marco L Davila, Salvatore Corallo, Bijal Shah, Kayla Reid, Michael D Jain, Sean J Yoder, Chaomei Zhang, Reginald Atkins, Meghan A Menges, Ling Cen, Jerald D Noble, Turab J Mohammad, Christina A Bachmeier, Samira Naderinezhad, Lanmin Zhang, Julieta Abraham Miranda, Julio C Chavez, Rebecca S Hesterberg, Luis Cuadrado Delgado, Constanza Savid-Frontera, John L Cleveland
Format: Article
Language:English
Published: BMJ Publishing Group 2025-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/7/e011807.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/7/e011807.full

Similar Items